glp 1 and kidney disease GLP-1 receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal glp-1 kidney disease news GLP-1s

A 2026 UK review of the neuroinflammation / white-matter / small-fibre mechanism, the 2025 BSR guideline, the BDNF / HGF/c-Met case, the elevated lymphoma risk vs pro-proliferative c-Met and why specialist care, not a peptide, comes first Read the full review Microbiome & Gut-Brain Neuroscience 16 June 2026 Dihexa for Gut-Brain Axis Brain Fog: IBS, SIBO, Leaky Gut, the Microbiome & the 2026 UK Review My guts a mess and so is my head are they connected? Increasingly, the science says they can be

2021;32(Suppl 5):S13267

*Proven via independent consumer study conducted over 4 weeks on 52 participants with sensitive skin

Diabetes 71 , 11151127 (2022)

Tesamorelin (Egrifta, Egrifta SV) is FDA-approved for the treatment of HIV-associated lipodystrophy (excess abdominal fat in HIV-positive patients on antiretroviral therapy)